Congress protects dialysis patients from insurance discrimination and cost-shifting

What it does

This bill amends Medicare law to prevent private health insurance plans from treating dialysis patients worse than other patients or shifting dialysis costs to Medicare. It clarifies that plans cannot single out dialysis services for coverage limits or restrictions that other medical services don't face, though plans can still choose which dialysis providers to include in their networks. The bill aims to protect end-stage renal disease patients from insurance discrimination.

Why we flagged it

The bill's core function is to prevent private insurers from discriminating against dialysis patients and shifting costs to Medicare, framed as a clarification of existing law rather than new regulation.

What the text implies

• The bill may trigger litigation over what constitutes 'disparate effect' on dialysis patients, potentially expanding insurer liability and compliance costs.
• By preserving network-composition flexibility while restricting benefit differentiation, the bill creates a narrow regulatory corridor: plans can limit dialysis providers but not dialysis coverage itself, which may lead to disputes over network adequacy.
• The reference to 42 CFR Part 411 enforcement standards may delegate significant interpretive authority to CMS, potentially creating regulatory uncertainty about what constitutes prohibited discrimination.
• Dialysis providers (DaVita, Fresenius) may benefit from reduced insurer pressure to negotiate lower rates, since plans cannot use coverage restrictions as leverage—this could indirectly raise costs for other patients or employers.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Dialysis patients gain explicit legal protection against insurance discrimination and cost-shifting to Medicare, ensuring they receive equitable coverage. However, the bill preserves plans' ability to limit provider networks, which may constrain patient choice within the protected benefit.

Who stands to gain

• dialysis patients (protected from cost-shifting)
• dialysis providers (reduced insurer negotiating leverage)
• Medicare (reduced cost-shifting from private plans)

Named in the bill

Medicare, Social Security Act, end-stage renal disease (ESRD), dialysis providers, private health insurance plans, CMS (Centers for Medicare & Medicaid Services), DaVita (DVA), Fresenius Medical Care, Bristol Myers Squibb (BMY), Grifols (GH), Pfizer (PFE), Johnson & Johnson (JNJ)

Where it stands

7 cosponsors: 5 Republicans, 2 Democrats.

• Mar 27, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 27, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

24 lobbying clients named this bill on 36 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $13,990,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Bill Cassidy, the sponsor, reported $1,329,254 in PAC receipts in the 2026 cycle. $14,000 of that came from 3 PACs tied to these lobbying clients.

• Lockheed Martin Corporation — $4,180,000 on 1 filing
• Boeing Company — $2,770,000 on 1 filing
• Fresenius Medical Care North America — $2,410,000 on 2 filings
• Davita Inc — $980,000 on 1 filing
• American Association of Nurse Practitioners — $950,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.